Sakar Healthcare Q1 Results: Net Profit Surges 120% as Oncology Pivot Gains Momentum
Sakar Healthcare delivered a robust performance in Q1 FY27, marked by a 120% jump in net profit and a significant expansion of its specialized oncology segment. The company is successfully transitioning toward a vertically integrated, export-led oncology model with improving operational margins.
Zydus Lifesciences and Apollo Hospitals Partner to Launch Shield Multi-Cancer Detection Test
Zydus Lifesciences has entered into a Memorandum of Understanding with Apollo Hospitals to expand access to the Shield Multi-Cancer Detection (MCD) test in India. This partnership utilizes Zydus's exclusive agreement with Guardant Health to provide a non-invasive, blood-based screening tool for 10 common cancer types.
Shilpa Medicare Commissions Integrated ADC Manufacturing Facility in Dharwad
Shilpa Biologicals Private Ltd, a subsidiary of Shilpa Medicare, has commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP manufacturing facility. Located in Dharwad, the plant enables end-to-end production of complex oncology biologics for global markets.
Shilpa Medicare Subsidiary Commissions Integrated ADC GMP Facility in Dharwad
Shilpa Biologicals Private Ltd, a subsidiary of Shilpa Medicare, has commissioned an integrated Antibody-Drug Conjugate (ADC) GMP manufacturing facility in Dharwad. This advanced unit enables the company to offer end-to-end development and production of complex oncology drug substances for the global pharmaceutical market.
Dr. Reddy's Launches First Generic Bosulif in US Market for $253.8M Opportunity
Dr. Reddy's Laboratories has launched the first-to-market generic version of Bosulif (Bosutinib Tablets 400mg) in the United States. This strategic oncology launch, executed in collaboration with MSN Laboratories, grants the company 180 days of generic drug exclusivity for this specific dosage strength.